XLO logo

Xilio Therapeutics (XLO)

Profile

Full Name

Xilio Therapeutics, Inc.

Ticker Symbol

XLO

Exchange

NASDAQ

Country

United States

IPO

October 22, 2021

Indexes

Not included

Employees

64

Key Details

Price

$0.71(+7.10%)

Market cap

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$6.34M

Annual EPS

-$1.09(+60.79% YoY)

PE ratio

-

Next earnings date

May 14, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price Performance

Price Range

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Shares Outstanding

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

EPS

Profit

Expenses

EBIT & EBITDA

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Liabilities

Debt

Equity & Capital

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

CAPEX

Free Cash Flow

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

ROA & ROE

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Analyst ratings

Recent major analysts updates

Nov 8, 24 Raymond James
Outperform
May 30, 23 Chardan Capital
Buy
May 11, 23 Chardan Capital
Buy
Jan 27, 23 Morgan Stanley
Overweight
Dec 21, 22 Chardan Capital
Buy
Nov 10, 22 Raymond James
Outperform
Aug 10, 22 Morgan Stanley
Overweight
Jan 10, 22 HC Wainwright & Co.
Buy
Nov 16, 21 Raymond James
Outperform
Nov 16, 21 Morgan Stanley
Overweight

Institutional Ownership

  • What is the ticker symbol for Xilio Therapeutics?
  • Does Xilio Therapeutics pay dividends?
  • What sector is Xilio Therapeutics in?
  • What industry is Xilio Therapeutics in?
  • What country is Xilio Therapeutics based in?
  • When did Xilio Therapeutics go public?
  • Is Xilio Therapeutics in the S&P 500?
  • Is Xilio Therapeutics in the NASDAQ 100?
  • Is Xilio Therapeutics in the Dow Jones?
  • When was Xilio Therapeutics's last earnings report?
  • When does Xilio Therapeutics report earnings?
  • Should I buy Xilio Therapeutics stock now?

What is the ticker symbol for Xilio Therapeutics?

The ticker symbol for Xilio Therapeutics is NASDAQ:XLO

Does Xilio Therapeutics pay dividends?

No, Xilio Therapeutics does not pay dividends

What sector is Xilio Therapeutics in?

Xilio Therapeutics is in the Healthcare sector

What industry is Xilio Therapeutics in?

Xilio Therapeutics is in the Biotechnology industry

What country is Xilio Therapeutics based in?

Xilio Therapeutics is headquartered in United States

When did Xilio Therapeutics go public?

Xilio Therapeutics's initial public offering (IPO) was on October 22, 2021

Is Xilio Therapeutics in the S&P 500?

No, Xilio Therapeutics is not included in the S&P 500 index

Is Xilio Therapeutics in the NASDAQ 100?

No, Xilio Therapeutics is not included in the NASDAQ 100 index

Is Xilio Therapeutics in the Dow Jones?

No, Xilio Therapeutics is not included in the Dow Jones index

When was Xilio Therapeutics's last earnings report?

Xilio Therapeutics's most recent earnings report was on Mar 11, 2025

When does Xilio Therapeutics report earnings?

The next expected earnings date for Xilio Therapeutics is May 14, 2025

Should I buy Xilio Therapeutics stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page